GlycoFlux™ Human AGL Overexpression HepG2 Cell Line (CAT#: GLJF-0925-JF608)

Description	GlycoFlux™ human AGL overexpression HepG2 cell line is a stable cell line engineered to express AGL, the glycogen debranching enzyme with dual 4-α-glucanotransferase and amylo-1,6-glucosidase activities. Essential for glycogen breakdown, mutations cause glycogen storage disease III with variable presentations. This model supports research on glycogen metabolism, liver and muscle physiology, and therapeutic intervention strategies.
Product Type	Overexpression Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:4~1:6
Cell Line	HepG2
Primary Disease	Hepatoblastoma
Lineage	Liver
Lineage Subtype	Hepatoblastoma

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Culture Medium	DMEM & FBS & Glutamine
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	AGL
Full Name	Amylo-Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase
Alternative Name	GDE
Location	1p21.2
Gene ID	178
Summary	This gene encodes the glycogen debranching enzyme, critical for glycogen breakdown. It carries two separate catalytic activities-4-alpha-glucanotransferase and amylo-1,6-glucosidase-at different sites. Mutations cause glycogen storage diseases, with variability likely influenced by tissue-specific alternative splicing. Distinct isoforms arise from alternative splicing.